Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Guillaume Pare
Dr. Jean-Philippe Collet ,
Presenter: Guillaume Pare | see Discussant report
BackgroundFixed-dose unmonitored treatment with dabigatran etexilate is effective and has a favorable safety profile in prevention of stroke in atrial fibrillation patients compared to warfarin. We hypothesized that genetic variants could contribute to inter-individual variability in blood concentrations of the active metabolite of dabigatran etexilate, and influence the safety and efficacy of dabigatran.
MethodsWe successfully conducted a genome-wide association study in 2,944 RE-LY participants. Single nucleotide polymorphisms (SNP) correlated with dabigatran peak and trough concentrations were tested for an association with reported bleeding event (N=587), major bleeding (N=101) and ischemic events (N=32).
ResultsThe CES1 SNP rs2244613 was associated with trough concentrations, and the ABCB1 SNP rs4148738 and CES1 SNP rs8192935 were associated with peak concentrations at genome-wide significance (P<9 x 10-8) with a gene-dose effect. Each minor allele of the CES1 SNP rs2244613 was associated with lower trough concentrations (15% decrease per allele, 95%CI 10-19%; P=1•2 x 10-8) and a lower risk of any bleeding (OR=0•67, 95%CI 0.55-0•82; P=7 x 10-5) in dabigatran-treated participants, with a consistent but non-significant lower risk of major bleeding (OR=0•66, 95%CI 0•43-1•01). The interaction between treatment (warfarin versus all dabigatran) and carrier status was statistically significant (P=0•002) with carriers having less bleeding with dabigatran than warfarin (HR=0•59, 95%CI 0•46-0•76; P=5•2 x 10-5) in contrast to no difference in noncarriers (HR=0•96, 95%CI 0•81-1•14; P=0•65). There was no association with ischemic events, and neither rs4148738 nor rs8192935 was associated with bleeding or ischemic events.
ConclusionsGenome-wide association analysis identified that carriage of CES1 rs2244613 minor allele occurred in 32•8% of patients in RELY and was associated with lower dabigatran exposure. The presence of the polymorphism was associated with a lower risk of bleeding.
Discussant: Jean-Philippe Collet | see Presenter abstract
711001 - 711002
Clinical Trial & Registry Update III: Updates on Atrial Fibrillation and Valves
© 2017 European Society of Cardiology. All rights reserved